Who Supplies Terbinafine to India from UNITED STATES

Importing finished pharmaceutical formulations containing Terbinafine into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Drug Import License from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with CDSCO, which involves submitting Form 40 or 41, depending on the product's classification. The registration process includes providing detailed product information, manufacturing site details, and stability data. The timeline for import drug registration can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory workload. For formulations under HS Code 30049099, specific requirements include proof of manufacturing, quality control measures, and compliance with the Indian Pharmacopoeia standards.

Upon arrival in India, each batch of Terbinafine formulations must undergo quality testing at a CDSCO-approved laboratory. This testing ensures that the product meets the standards set by the Indian Pharmacopoeia. A Certificate of Analysis (CoA) is required for each batch, detailing the product's composition, purity, and potency. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify compliance with import regulations and to prevent the entry of substandard or counterfeit drugs into the Indian market.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. However, the PLI scheme primarily targets domestic production and may not directly affect imports of finished formulations. Bilateral agreements between India and the United States have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which can expedite the import process for compliant products.

India imports finished Terbinafine formulations to meet the demand for branded or patented products not manufactured domestically. Specific dosage forms, such as certain tablet strengths or combination therapies, may not be produced locally, necessitating imports. While India has a robust pharmaceutical manufacturing sector, the import of finished formulations allows for a diverse product range and access to the latest therapeutic advancements. The market size for Terbinafine formulations in India is substantial, driven by the prevalence of fungal infections and the need for effective treatments.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the CIF (Cost, Insurance, and Freight) value. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is levied. There are no specific exemptions or concessional rates for imports from the United States under this HS code. The total landed duty percentage, combining BCD, IGST, and SWS, is approximately 23.6%.

India sources finished Terbinafine formulations from the United States due to the availability of patented formulations and specialized dosage forms not produced domestically. The United States' pharmaceutical industry is known for its high-quality standards and innovative products, providing a competitive advantage in the Indian market. Other suppliers, such as China and Germany, also export Terbinafine formulations to India; however, the United States maintains a significant share due to its established trade relations and product offerings.

India imports finished Terbinafine formulations from the United States to access patented formulations and specialized dosage forms not available domestically. The United States' pharmaceutical industry offers high-quality products that meet international standards, providing a competitive edge in the Indian market. Specific formulations, such as combination therapies or unique delivery systems, are sourced from the United States to fulfill unmet medical needs in India.

When compared to other origins like China and the European Union, the United States offers advantages in terms of product quality, regulatory compliance, and innovation. While Chinese and European suppliers may offer competitive pricing, the United States' adherence to stringent manufacturing standards and its established trade relations with India make it a preferred source for finished Terbinafine formulations.

Indian importers face potential risks when sourcing finished Terbinafine formulations from the United States, including currency fluctuations, regulatory changes, and shipping disruptions. Past shortages have been minimal, but importers should remain vigilant regarding geopolitical developments and global supply chain dynamics that could impact the availability and cost of imports.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Align procurement volumes with MOQs to optimize costs while meeting demand.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers to ensure compliance with quality and regulatory standards.

1. 1DGFT Import License: Obtain a valid license from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation.
3. 3Form 40/41 Submission: